Evidence map›Paper›PMID 42742702›Full record

ReviewArchives of toxicology2026

Genotoxicity of anthraquinone dyes and dye intermediates: a comprehensive review.

Anna Itkonen, Harri Kovakoski, Mikko Herrala, Jaana Rysä

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna Itkonen *School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.ORCID http://orcid.org/0000-0003-0508-8585
Harri Kovakoski *School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
Mikko HerralaSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.ORCID http://orcid.org/0000-0002-9260-2679
Jaana RysäSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland. jaana.rysa@uef.fi.ORCID http://orcid.org/0000-0003-2205-6323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anthraquinone dyes and dye intermediates are widely used across industrial, pharmaceutical, and biological applications. Despite evidence that both synthetic and naturally occurring anthraquinones may exhibit genotoxic effects, a complete assessment of their genotoxic potential is currently lacking. This review provides a comprehensive evaluation of genotoxicity data for anthraquinone dyes and dye intermediates derived from bacterial assays, mammalian in vitro systems, and in vivo models. Data from studies assessing gene mutation, chromosomal damage, DNA damage, and DNA repair were integrated. Genotoxic activity was common but substance-specific and frequently confined to particular endpoints or strains rather than consistent across the test battery. Of the 63 anthraquinones evaluated, ten including 1-amino-2-methyl-anthraquinone, 2-aminoanthraquinone, aloe emodin, chrysazin, emodin, Disperse Blue 3, Disperse Blue 7, Disperse Red 11, rubiadin and Acid Blue 62 showed consistent evidence of genotoxic activity, whereas carminic acid can be considered non-genotoxic on the available evidence. For many compounds the evidence remained insufficient to draw definitive conclusions, highlighting the need for further studies conducted in accordance with Organisation for Economic Co-operation and Development guidelines.

Indexed as

Chromosomal aberrationColourantDNA damageGene mutationMutagenicity

Identifiers

PMID42742702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.